Medical oncology and tumor pharmacotherapy最新文献_第2页

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987762

M Hansson, T Söderström

{"title":"The colony stimulating factors.","authors":"M Hansson, T Söderström","doi":"10.1007/BF02987762","DOIUrl":"https://doi.org/10.1007/BF02987762","url":null,"abstract":"Hematopoiesis is a dynamic process, which generate in the range of 10(9) cells/kg each day of erythroid and myeloid cells respectively. In vitro assays that were developed 20 years ago, have been used to define factors that can stimulate growth and differentiation of bone marrow (BM) derived progenitor cells. These growth factors for hematopoiesis were termed Colony Stimulating Factors (CSFs) since the assay system was to induce colonies. With the application of molecular biologic approaches, the genes encoding for these CSFs have been localized and cloned. Production of CSFs and other soluble signal substances (cytokines) as pure proteins have led to important insights into how hematopoiesis is regulated by a complex network made up by interactions between cells and cytokines. The availability of CSFs in clinically useful amounts has also led to clinical trials with new strategies for treating hematopoietic dysfunctions, congenital or acquired. Because others have recently reviewed clinical applications or basic science studies on the colony stimulating factors, we will summarize the two with focus on common features between the different CSFs.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 1-2","pages":"5-12"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987762","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19247573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 48

Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma. 低剂量环磷酰胺、干扰素及持续输注白介素-2治疗晚期肾细胞癌。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987776

J P Wersäll, G Masucci, A L Hjelm, P Ragnhammar, J Fagerberg, J E Frödin, K Merk, C Lindemalm, K Ericson, B Kalin

{"title":"Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma.","authors":"J P Wersäll, G Masucci, A L Hjelm, P Ragnhammar, J Fagerberg, J E Frödin, K Merk, C Lindemalm, K Ericson, B Kalin","doi":"10.1007/BF02987776","DOIUrl":"https://doi.org/10.1007/BF02987776","url":null,"abstract":"Pretreatment with a low dose of cyclophosphamide (CY) has been claimed to inhibit suppressor functions and augment various immune functions. A combination of a low dose of CY, alpha-interferon (IFN-alpha) and continuous infusion of interleukin-2 (IL-2) was used to treat patients with advanced renal cell cancer (RCC) (stage IV). Sixteen patients received four cycles consisting of CY (500 mg m-2) three days prior to daily i.m. injections of alpha-IFN (3 x 10(6) U), and continuous infusion of 18 x 10(6) IU rIL-2 for five days. The cycle interval was three weeks. Two patients had partial response (13%) (26+ and 12+ months), two had a minor response (9+ and 4 months), and three patients achieved stable disease (19+, 14+ and 8+ months). No patients required intensive care. Side effects were mainly fever, malaise, capillary leak syndrome and diarrhoea. Non-responders showed significantly higher eosinophil and platelet counts compared to responders. Serum concentration of IL-2 was significantly higher in responders. 5/11 patients had abnormally low values of serum thyroxine after therapy. Two patients needed thyroid hormone substitution. The difference between the initial and the lowest thyroxine values correlated significantly to survival (p < 0.03). The addition of CY to rIL-2 and IFN-alpha in the present protocol did not contribute to an increased major response rate.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 3","pages":"103-11"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987776","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19252830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Radon as a risk factor for extra-pulmonary tumours. 氡是肺外肿瘤的危险因素。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02989665

O Axelson, F Forastiere

引用次数: 13

Biology of monoclonal antibodies in tumor therapy. 单克隆抗体在肿瘤治疗中的生物学研究。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987764

C H Janson

引用次数: 3

Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma. 非霍奇金淋巴瘤的持续与间歇泼尼莫司汀治疗。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02989664

T Hatschek, L Baldetorp, J Carstensen, L Håkansson, T Möller, B Nilsson, B Termander

{"title":"Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma.","authors":"T Hatschek, L Baldetorp, J Carstensen, L Håkansson, T Möller, B Nilsson, B Termander","doi":"10.1007/BF02989664","DOIUrl":"https://doi.org/10.1007/BF02989664","url":null,"abstract":"Seventy-eight patients with advanced non-Hodgkin's lymphomas were randomized for treatment with prednimustine (Sterecyt) in two different schedules: either receiving continuous treatment at a dosage of 60 mg daily, or intermittent two-week courses with 200 mg daily for five days. The aim of the study was to compare efficacy and side effects of the two different schedules. Forty patients received continuous, and 38 patients intermittent treatment. Objective response was achieved in 66% of 71 evaluable patients, equally distributed between the two treatment arms. The 10-year survival rate was 20% (SE = 6%; continuous treatment) and 11% (SE = 5%; intermittent treatment), respectively (logrank p = 0.26). Median time to response, duration of response and time to progression showed no significant difference between the treatment groups. Median time on treatment was longer for patients treated continuously, probably due to more easily performed dose adjustments in such patients. There was a significant decrease of the white blood cell counts in patients who received prednimustine continuously compared with those treated according to the intermittent schedule (p = 0.02). No significant differences were found regarding the thrombocyte levels. The response rate was closely related to haematological toxicity (p = 0.01). Our results suggest that prednimustine in non-Hodgkin's lymphomas has similar effectiveness both in daily treatment and in a two-weekly intermittent schedule. Continuously given treatment may be easier to govern and, thereby, allow for higher treatment intensity. With respect to toxicity, daily doses of approximately 30-40 mg in previously untreated patients may be recommended.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 4","pages":"159-66"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989664","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19155461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients. 一种混合细菌疫苗在肿瘤患者中的临床结果和免疫效果。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02989663

H F Havas, R S Axelrod, M M Burns, D Murasko, M Goonewardene

{"title":"Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients.","authors":"H F Havas, R S Axelrod, M M Burns, D Murasko, M Goonewardene","doi":"10.1007/BF02989663","DOIUrl":"https://doi.org/10.1007/BF02989663","url":null,"abstract":"A biological response modifier, mixed bacterial vaccine (MBV), derived from Streptococcus pyogenes and Serratia marcescens was used as a single agent in the treatment of 11 patients with refractory malignancies. MBV's effect on interleukin-2 (IL-2) production, plasma interferon (IFN) and tumor necrosis factor (TNF) levels was monitored. Most patients' peripheral blood mononuclear cells continued to produce baseline to elevated levels of IL-2, in spite of age and disease status. Several patients maintained moderate to high IFN levels. In general there was little correlation between IL-2 and IFN levels or with the response to therapy. One of 11 patients had minor response, 1 of 11 had partial response, 4 of 11 had temporary stabilization of disease, and 5 of 11 had progressive disease. A patient with AIDS and Kaposi's sarcoma experienced a dramatic improvement in performance status and disease stabilization. In all patients side effects occurred only following i.v. and not i.m. administration and included fever and chills. No adverse hepatic, renal or hematologic effects were observed. MBV is a well-tolerated biological response modifier with modest activity in advanced human tumors.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 4","pages":"145-58"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989663","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18520413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Morphometric, DNA and PCNA in thin malignant melanomas. 薄型恶性黑色素瘤的形态计量学、DNA和PCNA。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987774

V Björnhagen, E Månsson-Brahme, J Lindholm, A Mattsson, G Auer

引用次数: 11

Expression of an adhesion molecule and homing in B-cell chronic lymphocytic leukaemia: II. L-selectin expression mediated cell adhesion revealed by immobilized analogue carbohydrates in B-cell chronic lymphocytic leukaemia and monoclonal lymphocytosis of undetermined significance. b细胞慢性淋巴细胞白血病中粘附分子的表达和归巢:ⅱ。l -选择素表达介导的固定碳水化合物在b细胞慢性淋巴细胞白血病和单克隆淋巴细胞增多症中的细胞粘附作用

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02989666

G Csanaky, J A Vass, H Losonczy, M Schmelczer

{"title":"Expression of an adhesion molecule and homing in B-cell chronic lymphocytic leukaemia: II. L-selectin expression mediated cell adhesion revealed by immobilized analogue carbohydrates in B-cell chronic lymphocytic leukaemia and monoclonal lymphocytosis of undetermined significance.","authors":"G Csanaky, J A Vass, H Losonczy, M Schmelczer","doi":"10.1007/BF02989666","DOIUrl":"https://doi.org/10.1007/BF02989666","url":null,"abstract":"The L-selectin mediated adhesion of freshly isolated peripheral blood mononuclear cells (PBMCs) to phosphonomonoester core polysaccharide (PPME) and fucoidin derivatized gels was investigated in seven cases of monoclonal lymphocytosis of undetermined significance (B-MLUS) and 12 cases of chronic lymphocytic leukaemia: B-CLL, patients with peripheral lymphocytosis (LY-patients), lymph node enlargement (LN-patients) and splenomegaly (SM-patients). PBMCs isolated from the peripheral blood of 10 healthy donors served as controls. The binding to PPME and fucoidin correlated well (n = 19, P = 0.01). Adhesion of PBMCs from B-MLUS and B-CLL showed a greater variability than controls. A higher number of cells, on average, bound to PPME and fucoidin derivatized polyacrylamide gels in B-MLUS than in B-CLL. However, the differences observed were not statistically significant. In four cases with B-CLL, the stimulatory effect of interferon-alpha on the function of L-selectin and some other accessory molecules was also studied. The increased binding of PBMCs to immobilized analogue molecules (PPME, fucoidin) and to high endothelial venules (HEVs) in the in vitro HEV-binding assay supports the notion that interferon-alpha not only increases the expression of the adhesion molecules, but also results in an enhanced adhesive function.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 4","pages":"173-80"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989666","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19157397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Treatment of ovarian cancer: the state of the art. 卵巢癌的治疗:最先进的。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987781

N Einhorn

引用次数: 0

Ultrastructural investigation of DNA in megakaryoblastic leukemia by using osmium-ammine-B: comparison with several types of leukemia. 锇胺b对巨核母细胞白血病DNA超微结构的研究:与几种类型白血病的比较。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987778

Y Ohwada, M Eguchi

引用次数: 0